



Supplementary Figure 1

Supplementary Figure 1. Characterization of the $KP^{wm/+}C$ mouse model and derived cell lines. **A and B**, The overall survival and disease-specific survival between $KP^{wm/+}C$ and $KP^{fl/+}C$ PDAC models as determined by the log-rank (Mantel-Cox) test. **C and D**, The overall survival and disease-specific survival between $KP^{wm/+}C$ and $KP^{LSL/+}C$ PDAC models as determined by the log-rank (Mantel-Cox) test. **E**, The timeline of PDAC progression is histologically similar between $KP^{wm/+}C$ and $KP^{fl/+}C$ PDAC models. Scale bars, 200 μ M. **F**, All murine and human PDAC cell lines underwent Sanger sequencing to confirm *p53* missense mutations (listed) and to exclude the presence of wildtype *p53* alleles. **G**, Transwell migration/invasion assays of PDAC cell lines derived from pancreas tumors in $KP^{wm/+}C$ mice and human PDAC cell lines (MDA-PATC) following mutant *p53* knockdown. **H**, The effects of ectopic mutant *p53*^{R172H} expression on PDAC cell migration and invasion in *p53*-null, $KP^{fl}C$ cell lines. **I**, GSEA analysis of hallmark pathways in $KP^{wm/+}C$ tumors reveals dysregulated pathways similar to human PDAC. **(G, H)** Data are quantified by 20X fields as mean \pm s.d. and pooled from at least two independent experiments performed in triplicate. P values determined by unpaired two-tailed t-tests.